Univest analyzes Nephro Care India's valuation and peers
Univest releases research on Nephro Care India’s valuation and peer comparison. The report highlights P/E of 32x and EV/EBITDA of 18x, positioning it as premium to sector peers. Liquidity and scalability remain key concerns for investors.
📊 STOCKS: NEPHROCARE | 🏢 SECTOR: CapitalMarkets | #LOWIMPACT #Valuation
This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.